The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 15, 2025
Filed:
Nov. 14, 2019
The Broad Institute, Inc., Cambridge, MA (US);
Dana-farber Cancer Institute, Inc.;
Instituto Carlos Slim DE LA Salud, A.c., Mexico City, MX;
Steven Corsello, Boston, MA (US);
Ryan Spangler, Cambridge, MA (US);
Rohith Nagari, Cambridge, MA (US);
Todd Golub, Cambridge, MA (US);
Amael Madec, Cambridge, MA (US);
THE BROAD INSTITUTE, INC., Cambridge, MA (US);
DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US);
INSTITUTO CARLOS SLIM DE LA SALUD, A.C., Mexico City, MX;
Abstract
The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of FOXA1 and/or FOXA1 gene targets, such as certain breast, liver and/or prostate cancers, including luminal and/or ER-positive forms of breast cancer. Three previously identified adenosine receptor antagonists, CGS-15943, MRS-1220 and SCH-58261, as well as furan ring moiety-possessing derivatives of CGS-15943 are specifically provided for killing cancer cells in a manner that appears to involve activation of the aryl hydrocarbon receptor (AHR) by such compounds. The instant disclosure therefore provides for selecting and/or administering CGS-15943, MRS-1220, SCH-58261 and/or a furan-possessing derivative of CGS-15943, MRS-1220 and/or SCH-58261 as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.